Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Articles

Dr. Monk on the Utility of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer

August 19th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

July 28th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Managing AEs With Pembrolizumab and Lenvatinib

June 1st 2021

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer

June 1st 2021

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

A Discussion on the Study 309/KEYNOTE-775 Data

May 25th 2021

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Results from Study 309/KEYNOTE-775

May 25th 2021

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Dr. Monk on Guidelines for Maintenance PARP Inhibitors in Ovarian Cancer

May 19th 2021

Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.

Study 309/KEYNOTE-775 Trial Design

May 18th 2021

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Therapeutic Approaches in Endometrial Cancer

May 18th 2021

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Dr. Monk on the Clinical Implications of the PRIMA Trial in Advanced Ovarian Cancer

April 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the clinical implications of the phase 3 PRIMA trial in newly diagnosed advanced ovarian cancer.

Future of Advanced Endometrial Cancer

January 4th 2021

Novel Targets for Advanced Endometrial Cancer

January 4th 2021

Endometrial Cancer: Chemo-Free Regimens on the Horizon

January 4th 2021

Emerging Agents: Treatment of Endometrial Cancer

January 4th 2021

Sequencing for Advanced Endometrial Cancer

January 4th 2021

Recurrent Endometrial Cancer: Safety of Combination Therapy

January 4th 2021

Combination Therapy for Recurrent Endometrial Cancer

January 4th 2021

Emerging ICI Therapy for Advanced Endometrial Cancer

January 4th 2021

Immune Checkpoint Inhibitors in Advanced Endometrial Cancer

January 4th 2021

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

January 4th 2021